ArticleAntibiotics (Basel, Switzerland)2022
Antimicrobial Potential of Conjugated Lignin/Morin/Chitosan Combinations as a Function of System Complexity.
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Optimization of Fermentation Condition to Enhance Postbiotic Yield and Bio-Functional Efficacy from Lactobacillus-Bifidobacterium Strains Co-Fermentation.Probiotics and antimicrobial proteins · 2026Article
- Article
- Ameliorated Hepatoprotective Aptitude of Novel Lignin Nanoparticles on APAP-Induced Hepatotoxicity in a Murine Model.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Innovative In Situ Interfacial Co-Assembled Lignin/Chitosan Nanoparticles-Green Synthesis, Physicochemical Characterization, In Vitro Release, and Intermolecular Interactions.International journal of molecular sciences · 2025Article
- Menadione Contribution to the In Vitro Radical Scavenging Potential of Phytochemicals Naringenin and Lignin.International journal of molecular sciences · 2023Article
- Newly Synthesized Lignin Microparticles as Bioinspired Oral Drug-Delivery Vehicles: Flavonoid-Carrier Potential and In Vitro Radical-Scavenging Activity.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
As natural biopolymers, chitosan and lignin are characterized by their good biocompatibility, high biodegradability and satisfactory biosafety. The active polymers’ functional groups are responsible for the potential of these biomaterials for use as carrier matrices in the construction of polymer−drug conjugates with prospective applicability in the fields of medicine, food and agriculture—subjects that have attracted attention in recent years. Hence, the aim of this research was to place substantial emphasis on the antimicrobial potential of flavonoid−biopolymer complex systems by assessment of the probable synergetic, additive or antagonistic effects arising as a function of systemic complexity. The joint implementation of morin, chitosan and lignin in conjugated two- and three-component systems provoked species-dependent antimicrobial synergistic and/or potentiation effects against the activity of the tested bacterial strains Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and the clinical isolate Bacillus cereus. The double combinations of morin−chitosan and morin−lignin resulted in a 100% increase in their inhibitory activity against S. aureus as compared to the pure biocompounds. The inhibitory effects of the three-component system, in decreasing order, were: S. aureus (IZ = 15.7 mm) > P. aeruginosa (IZ = 15 mm) > B. cereus and E. coli (IZ = 14 mm). All tested morin-containing two- and three-component systems exhibited clear and significant potentiation effects, especially against S. aureus and B. cereus. The results obtained are a prerequisite for the potential use of the studied conjugated lignin−morin−chitosan combinations in the construction of novel drug-carrier formulations with improved bioactivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.